FOI Request
- Disclosure ID
- FOI/02453
- Request Date
- May 18, 2018
- Subject
- Intra-Vitreal Injections/Implants [Jan-April 2018]
- Description
Within your trust how many intra-vitreal injections/implants have been used in the latest 4 months, if possible between January to April 2018 If your trust is able to identify injections/implants by eye conditions please split by the drug used [ranibizumab, bevacizumab, aflibercept, Fluocinolone and Dexamethasone].
- Response
Please see below the number of doses issued by our Pharmacy, this may not necessarily correlate with the actual doses administered. Our Pharmacy electronic prescribing system does not record the clinical diagnosis, as such we are not able to state whether they were dispensed for Wet AMD.
This data is for January to April 2018
Lucentis (ranibizumab) Injections Avastin (bevacizumab) Injections Eylea (aflibercept) Injections Illuvien (Fluocinolone) Impants Ozudex (Dexamethasone) Implants Total 495 0 966 0 24 Wet Age Related Macular Degeneration (wAMD) Diabetic Macular Oedema (DMO) Retinal Vein Occlusion – Central or Branch (CRVO or BRVO) Other eg mCNV